Sever Pharma Solutions is a full-service CDMO specializing in advanced polymer drug products and packaging, including high-potent APIs. We focus on cost-efficient development and reliable large-scale production of high-value products. Our experts in polymers and extrusion design robust, scalable delivery systems, supported by a dedicated Hot Melt Extrusion team in the USA.
SEPTODONT INC
Septodont is recognized as the world leader in local anesthetics for the Dental profession. Providing a complete line of local anesthetics as well as anesthetic accessories. | Septodont is a world leader in the development, manufacturing, and distribution of innovative dental products. We leverage our decades of expertise to create end-to-end value for our global dental and pharmaceutical partners.
Scientist.com
Scientist.com is the world’s largest enterprise marketplace for outsourced R&D services. It saves time and money and provides access to innovation while maintaining compliance with an organization’s procurement policies. Scientist.com operates private marketplaces for most of the world’s major pharmaceutical companies and the US NIH. Visit scientist.com to learn more.
Scientific Solutions, LLC
Full-service histology lab providing quality histology and pathology evaluation for GLP and non-GLP preclinical and clinical studies. Long term archiving of study materials.
Sanofi Global
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
RoukenBio
We take our tagline seriously. We’re disrupting the traditional CRO model with our collaborative, personalised approach to drug discovery. With customers in over 27 countries globally, our aim is to become the most trusted research partner to biotherapeutic innovators. Backed by brilliant minds, we offer a range of in vitro bioassay services from immunology, bioanalytical, cell line engineering, development of bioassays, to safety and efficacy assessments. Working across inflammation, auto-immunity, immuno-oncology and oncology, we focus on novel and emerging therapeutic classes. We embrace change and drive innovation with unique services, like our customisable IndEx-2 cell line platform, to stay ahead of the curve. Our assays recreate disease stare pathologies as faithfully as possible, driving your drug discovery journey forward.
Rommelag USA
BLOW-FILL-SEAL ADVANCED ASEPTIC LIQUID PACKAGING Rommelag® provides Advanced Aseptic liquid packaging solutions with its Blow/Fill/Seal technology. BFS is the standard packaging technology for preservative-free unit-dose ophthalmic drugs. It has the highest Aseptic Assurance Level available. BFS is now available with Preservative Free Multi-Dose (PFMD) formats. mail.romus@rommelag.com or visit us at www.rommelag.com
Ritedose Corp
Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company’s process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com | The Ritedose Corporation is an industry leader in the CDMO, generic and 503B outsourcing markets. Founded in 1995 in Columbia, S.C., we use aseptic cGMP manufacturing and advanced blow-fill-seal (BFS) technology to ensure sterile, efficient and safe unit dose delivery. With its recent land acquisition, Ritedose operates entirely from a 130-acre campus in South Carolina. Ritedose has more than 575 employees and occupies 273,000 square feet of development, manufacturing and packaging space, driving an annual capacity of 2+ billion units. With the newly announced formation of Ritedose Performance Park and the buildout of an additional 225,000 sq ft Central Distribution Center, Ritedose will occupy over a half million sq ft under roof. Our highly touted, 27-year track record since 2012, includes delivery of more than 10 billion doses without a single interruption, and an exceptional inspection history and compliance record as noted by regulators, including the FDA. The Ritedose CDMO team shepherds products from early phase clinicals to commercial scale in an average 18 to 20 days from formulation to shipment and deploys rigorous environmental controls eliminating problems before they occur. The division produces both branded and generic solutions. Ritedose produces suspensions and emulsions for the inhalation, ophthalmic, otic and oral markets. Ritedose Pharmaceuticals provides an uninterrupted, reliable supply chain of unit dose generic inhalation medication for wholesalers and major pharmacy chains across the U.S. Our competitive pricing, aseptic manufacturing platform and packaging innovations allow our partners to feel confident in the products they offer to service patients. Our 503B outsourcing division delivers on-demand, pre-filled critical care syringe products that save valuable time in the pharmacy for clinicians who are stretched thin. Our innovative packaging allows for extended product dating of up to 360 days at room temperature storage. Appropriate product labeling and reliable concentrations facilitate safe patient care reducing potential bedside errors.
Revolution Medicines
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.